Flanvotumab
Modify Date: 2024-04-03 18:36:35
Flanvotumab structure
|
Common Name | Flanvotumab | ||
|---|---|---|---|---|
| CAS Number | 1188277-05-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of FlanvotumabFlanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance[1]. |
| Name | Flanvotumab |
|---|
| Description | Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Flanvotumab is based on TA99, a murine IgG2a anti-TYRP1 mAb, localizes to subcutaneous melanoma xenografts and inhibits syngeneic tumor growth in preclinical models[1]. TA99 exhibits antitumor effect depending on the intact antibody, the presence of Fc receptor, and natural killer (NK) cells[1]. |
| References |
| No Any Chemical & Physical Properties |